Back
KLBF - Kalbe Farma

KLBF - Managing production costs to maintain performance

12 February 2025

KLBF - Managing production costs to maintain performance Kalbe Farma (KLBF) will continue to manage its production costs to maintain performance, this year. Moreover, KLBF will focus on: 1) its prescription drug segment by developing biological drugs, cell therapy, and vaccines, 2) healthcare products segment by developing wellness and preventive products, 3) nutritionals segment by developing products in liquid form, and 4) distribution and logistics segment by fostering new partnerships and developing medical devices. In order to achieve them, KLBF has allocated around IDR1 tn for this year' capex. Thus, KLBF expects its topline and bottom line to grow by 8-10% yoy, respectively this year. (Source : Kontan)

Related Research

Consumer
KLBF - Stronger growth and margins expansion
Andre Suntono 12 July 2023 See Detail
Consumer
KLBF - Performa solid pada kuartal pertama tahun 2022
Winny Rahardja 10 May 2022 See Detail
Consumer
KLBF - Expects a Brighter 24F, after a weak 23f
Andre Suntono 20 March 2024 See Detail